Genovis ABOSTO:GENO +0.52%84 EBITDA Margin % is 28.38% as of Mar. 2026, which is 53% above its 10-year median of 18.51. GuruFocus rates OSTO:GENO with a GF Score™ of 84/100 and a GF Value™ of kr28.45 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 943 Biotechnology companies, Genovis AB ranks better than 87.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genovis AB's EBITDA for the
three
months ended in Mar. 2026 was kr9.5 Mil. Genovis AB's Revenue for the
three
months ended in Mar. 2026 was kr33.5 Mil. Therefore, Genovis AB's EBITDA margin for the quarter that ended in Mar. 2026 was 28.38%.
Genovis AB (OSTO:GENO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genovis AB EBITDA Margin % Related Terms
Genovis AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genovis AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genovis AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genovis AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a EBITDA Margin % of 28.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genovis AB and its competitors. This is 53% above median its historical median of 18.51. According to the industry distribution chart, Genovis AB ranks #121 out of 943 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Genovis AB's EBITDA Margin % too high?
Genovis AB's current EBITDA Margin % of 28.38% is 53% above median its 10-year median of 18.51. Based on the distribution chart, Genovis AB ranks #121 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovis AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #121 out of 943 companies for EBITDA Margin %. This places Genovis AB in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genovis AB and its competitors. Genovis AB's current EBITDA Margin % is 28.38%, which is 53% above median its own 10-year median of 18.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr28.45, compared to a current price of kr19.46 — trading 31.6% below its estimated fair value. The current EBITDA Margin % is 28.38%, which is 53% above median its 10-year median of 18.51. Genovis AB's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current EBITDA Margin % is 28.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr19.46 is trading 31.6% below its estimated GF Value™ of kr28.45.
GuruFocus considers Genovis AB to be Significantly Undervalued.
Key valuation signals for OSTO:GENO:
EBITDA Margin %: 28.38% (53% above median its 10-year median of 18.51)
GF Value™: kr28.45 vs. price of kr19.46 (31.6% below fair value)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
84GF Score
Get the complete analysis for OSTO:GENO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
